VVOS (Vivos Therapeutics) Total Stockholders Equity: $-1.14 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VVOS Vivos Therapeutics Inc VVOS
43 GF Score
Price $0.39
GF Value $1.15
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vivos Therapeutics Total Stockholders Equity?

Vivos Therapeutics VVOS -3.32% 43 Total Stockholders Equity is $-1.14 Mil as of Mar. 2026. GuruFocus rates VVOS with a GF Score™ of 43/100 and a GF Value™ of $1.15 (Possible Value Trap). The stock has 6 warning signs investors should review.

Vivos Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-1.14 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Vivos Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Vivos Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 was -10.78.

Vivos Therapeutics  (NAS:VVOS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Vivos Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-1.138-0)/13.486
=-0.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Vivos Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(8.099 + 4.169) / -1.138
=-10.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivos Therapeutics Total Stockholders Equity Related Terms

Vivos Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Vivos Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivos Therapeutics Total Stockholders Equity Chart

Vivos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 25.54 4.80 0.41 7.95 -1.49

Vivos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.41 4.58 2.53 -1.49 -1.14
VVOS
43GF Score
Vivos Therapeutics Inc VVOS
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-1.14 Mil mean?
Vivos Therapeutics (VVOS) has a Total Stockholders Equity of $-1.14 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vivos Therapeutics and its competitors.
Is Vivos Therapeutics' Total Stockholders Equity too high?
Vivos Therapeutics' current Total Stockholders Equity is $-1.14 Mil. Overall, Vivos Therapeutics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Total Stockholders Equity compare to XAIR and TNON?
Vivos Therapeutics' Total Stockholders Equity of $-1.14 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vivos Therapeutics and its competitors. Vivos Therapeutics's current Total Stockholders Equity is $-1.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.15, compared to a current price of $0.39 — trading 66% below its estimated fair value. The current Total Stockholders Equity is $-1.14 Mil. Vivos Therapeutics' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Total Stockholders Equity is $-1.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivos Therapeutics (VVOS) Overvalued in 2026?

Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued. The current stock price of $0.39 is trading 66% below its estimated GF Value™ of $1.15. GuruFocus considers Vivos Therapeutics to be Possible Value Trap.

Key valuation signals for VVOS:

  • Total Stockholders Equity: $-1.14 Mil
  • GF Value™: $1.15 vs. price of $0.39 (66% below fair value)
  • GF Score™: 43/100 with 6 warning signs

No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivos Therapeutics Business Description

Address 7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
43GF Score

Get the complete analysis for VVOS

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price
$1.15
GF Value